Infectious Diseases (all articles) | Page 71 of 298 | Links Medicus Content Curation & Alerts in Medicine

Convalescent plasma is a transfusion of blood plasma from someone who has recovered from #COVID19, and is used as a treatment for COVID19 https://t.co/Bobq7OTDGq pic.twitter.com/pfO1sFvUpJ

— World Health Organization (WHO) (@WHO) December 7, 2021

A first, small study suggests Omicron is a larger threat to Covid-19 immunity than other variants.

8 Dec, 2021 | 10:22h | UTC

A first, small study suggests Omicron is a larger threat to Covid-19 immunity than other variants – STAT

Original Study: SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection – medRxiv

Commentary from the author on Twitter (thread – click for more)

We have completed our first experiments on neutralization of Omicron by Pfizer BNT162b2 vaccination elicited immunity

Manuscript available at https://t.co/rGaEB9GdmS

and should be available on medRxiv in the coming days

— Alex Sigal (@sigallab) December 7, 2021

RCT: In patients with severe Covid-19, high-flow oxygen therapy reduced the likelihood of invasive mechanical ventilation and decreased the time to clinical recovery compared to conventional oxygen therapy.

8 Dec, 2021 | 10:15h | UTC

Effect of High-Flow Oxygen Therapy vs Conventional Oxygen Therapy on Invasive Mechanical Ventilation and Clinical Recovery in Patients With Severe COVID-19: A Randomized Clinical Trial – JAMA

Non-invasive respiratory support in the management of acute COVID-19 pneumonia: considerations for clinical practice and priorities for research – “The two randomized controlled trials indicate superiority of non-invasive ventilation over high-flow nasal oxygen in reducing the need for intubation”.

[Preprint] RCT: non-invasive respiratory strategies in acute respiratory failure in patients with COVID-19 – CPAP reduced the composite outcome of intubation or death within 30 days; high-flow nasal oxygenation was not associated with better outcomes.

Phase 2 RCT: Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule.

8 Dec, 2021 | 10:12h | UTC

Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials – The Lancet Infectious Diseases

Invited Commentary: Booster doses for inactivated COVID-19 vaccines: if, when, and for whom – The Lancet Infectious Diseases

Video | COVID-19 Update: Omicron Variant.

8 Dec, 2021 | 10:09h | UTC

COVID-19 Update: Omicron Variant – JAMA

Beyond Omicron: what’s next for COVID’s viral evolution.

8 Dec, 2021 | 10:06h | UTC

Beyond Omicron: what’s next for COVID’s viral evolution – Nature

Editorial: Omicron is bad, but the global response is worse – “The pandemic will not end while vaccine equity keeps getting pushed to the margins”.

8 Dec, 2021 | 10:07h | UTC

Omicron is bad but the global response is worse – Nature

Case series with 139 adolescents and young adults with suspected myocarditis following mRNA vaccination showed most cases had a mild clinical course and rapid resolution of symptoms.

7 Dec, 2021 | 10:19h | UTC

Clinically Suspected Myocarditis Temporally Related to COVID-19 Vaccination in Adolescents and Young Adults – Circulation

News Release: Young people recover quickly from rare myocarditis side effect of COVID-19 vaccine – American Heart Association

Study shows increased immunogenicity of extended mRNA SARS-CoV-2 vaccine dosing intervals.

7 Dec, 2021 | 10:21h | UTC

Immunogenicity of Extended mRNA SARS-CoV-2 Vaccine Dosing Intervals – JAMA

Commentary on Twitter (thread – click for more)

1/ Not surprisingly, a longer delay between 1st & 2nd doses of mRNA COVID vaccines (i.e. 6-7 weeks rather than 3-4 weeks) results in better immune responses.https://t.co/XhiU6u0hYb

— Céline Gounder, MD, ScM, FIDSA 🇺🇦 (@celinegounder) December 3, 2021

The risk of postoperative complications following major elective surgery in active or resolved COVID-19 in the United States – Major, elective surgery 0–4 weeks after Covid-19 is associated with greatly increased risk of postoperative complications; surgery performed 4–8 weeks after infection is still associated with an increased risk of pneumonia.

7 Dec, 2021 | 10:23h | UTC

The Risk of Postoperative Complications following Major Elective Surgery in Active or Resolved COVID-19 in the United States – Annals of Surgery

Guideline: SARS‐CoV‐2 infection, COVID‐19 and timing of elective surgery

Study from 116 countries suggests surgery should be delayed for at least seven weeks following a COVID-19 diagnosis to reduce mortality risk

ASA Guidance: Preoperative testing for COVID-19 is essential, regardless of vaccination.

Position statement: Perioperative management of post-COVID-19 surgical patients.

Cohort study: Postoperative in-hospital mortality of patients with COVID-19 infection was more than double that in patients without COVID-19

The world has the tools to end the coronavirus pandemic. They’re not being used properly.

7 Dec, 2021 | 10:15h | UTC

The world has the tools to end the coronavirus pandemic. They’re not being used properly – CNN

Care of older people and people requiring palliative care with COVID-19: guidance from the Australian National COVID-19 Clinical Evidence Taskforce.

7 Dec, 2021 | 10:12h | UTC

Care of older people and people requiring palliative care with COVID-19: guidance from the Australian National COVID-19 Clinical Evidence Taskforce – Medical Journal of Australia

WHO Report: More malaria cases and deaths in 2020 linked to COVID-19 disruptions.

7 Dec, 2021 | 08:55h | UTC

News Release: More malaria cases and deaths in 2020 linked to COVID-19 disruptions – World Health Organization

Report: World Malaria Report 2021 – World Health Organization

Commentaries:

More people died of malaria in 2020 than in 2019. Here’s why – NPR

Malaria kills 180,000 more people annually than previously thought, says WHO – The Guardian

Commentary on Twitter (thread – click for more)

#COVID19 pandemic has disrupted #malaria services, leading to a marked increase in cases and deaths: 14 million more cases in 2020 compared to 2019, and 69,000 more deaths – new report.
➡️https://t.co/M9sNo2Pn4u #EndMalaria pic.twitter.com/g6MKFVpQKf

— World Health Organization (WHO) (@WHO) December 6, 2021

Perspective | ‘It’s misinformation at worst.’ Weak health studies can do more harm than good, scientists say.

7 Dec, 2021 | 10:17h | UTC

‘It’s misinformation at worst.’ Weak health studies can do more harm than good, scientists say – Science

Review of 4,470 cases of Multisystem Inflammatory Syndrome in Children in the US.

7 Dec, 2021 | 10:08h | UTC

Multisystem Inflammatory Syndrome in Children—United States, February 2020–July 2021 – Clinical Infectious Diseases

WHO issues guidelines on the treatment of children with multisystem inflammatory syndrome associated with COVID-19.

An Update on Multisystem Inflammatory Syndrome in Children Related to SARS-CoV-2.

Ten Things to Know About Multisystem Inflammatory Syndrome in Children (MIS-C).

Cohort study: long term follow-up showed most patients with post–COVID-19 Multisystem Inflammatory Syndrome in Children had good outcomes with no significant medium- or long-term sequelae.

Kawasaki Disease and Multisystem Inflammatory Syndrome in Children: An Overview and Comparison.

Cohort study: Six month follow-up of Multisystem Inflammatory Syndrome in Children.

Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, there was no evidence that recovery differed after primary treatment with intravenous immune globulin (IVIG) alone, IVIG plus glucocorticoids, or glucocorticoids alone.

Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, initial treatment with intravenous immune globulin (IVIG) plus glucocorticoids was associated with a lower risk of new or persistent cardiovascular dysfunction than IVIG alone.

Cohort study showed that the incidence of Multisystem Inflammatory Syndrome in Children (MIS-C) was 316 persons per 1 000 000 SARS-CoV-2 infections in persons younger than 21 years. The incidence was higher among Black, Hispanic or Latino, and Asian or Pacific Islander persons.

Cohort study showed good recovery for most children 6 months after Pediatric Inflammatory Multisystem Syndrome (PIMS-TS) associated with SARS-CoV-2.

Epidemiology of Multisystem Inflammatory Syndrome in Children: A Step Closer to Understanding Who, Where, and When

Neurologic involvement in children and adolescents with COVID-19 or Multisystem Inflammatory Syndrome

Clinical Update: Acute covid-19 and multisystem inflammatory syndrome in children

Differences in characteristics and outcomes of children and adolescents with Multisystem Inflammatory Syndrome in Children (MIS-C) vs. severe acute COVID-19

Cutaneous findings in SARS-CoV-2-associated Multisystem Inflammatory Disease in Children (MIS-C)

SR: Multisystem inflammatory syndrome in children related to COVID-19

Observational study: The combination of Immunoglobulins + Methylprednisolone was associated with a better course of fever compared to Immunoglobulins alone in Multisystem Inflammatory Syndrome in children

ACR Guidance for pediatric patients with multisystem inflammatory syndrome in children associated with SARS‐CoV‐2

New systematic review of Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 infection summarizes the clinical features, management, and outcomes of the disease, showing favorable outcomes for the majority of children

IDSA Guidance on the Treatment of AmpC β-lactamase-Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections.

7 Dec, 2021 | 08:49h | UTC

Infectious Diseases Society of America Guidance on the Treatment of AmpC β-lactamase-Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections – Clinical Infectious Diseases

RCT: Maribavir for refractory Cytomegalovirus infections with or without resistance post-transplant.

7 Dec, 2021 | 08:37h | UTC

Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results from a Phase 3 Randomized Clinical Trial – Clinical Infectious Diseases

Clinical Review: Management of pneumonia in critically ill patients.

7 Dec, 2021 | 08:41h | UTC

Management of pneumonia in critically ill patients – The BMJ

Systematic Review: Current practices of management of maternal and congenital Cytomegalovirus infection during pregnancy after a maternal primary infection occurring in first trimester of pregnancy.

7 Dec, 2021 | 08:35h | UTC

Current practices of management of maternal and congenital Cytomegalovirus infection during pregnancy after a maternal primary infection occurring in first trimester of pregnancy: Systematic review – PLOS One

Six different COVID-19 boosters are safe and increase immunity when given after two doses of AstraZeneca or Pfizer-BioNTech, with significant variations in immune responses, UK trial shows.

5 Dec, 2021 | 23:57h | UTC

News Release: Six different COVID-19 boosters are safe and increase immunity when given after two doses of AstraZeneca or Pfizer-BioNTech, with large variations in immune responses, UK trial shows – The Lancet

Original Study: Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial – The Lancet

Commentaries:

Six different COVID-19 boosters induce variable immune response – CIDRAP

Covid booster shots significantly strengthen immunity, trial finds – The Guardian

Expert reaction to COV-BOOST study investigating safety and immunogenicity of seven COVID-19 vaccines as a third dose following two doses of either Oxford-AstraZeneca or Pfizer – Science Media Centre

Commentary on Twitter

NEW—Six different COVID-19 boosters are safe and increase immunity when given after two doses of #AstraZeneca or #Pfizer-BioNTech, with large variations in immune responses, UK trial shows. https://t.co/ktUp1m2Rsb pic.twitter.com/wlwxcLYDm1

— The Lancet (@TheLancet) December 2, 2021

European data on Omicron: Out of 109 cases confirmed so far, all cases for which there is available information on severity were either asymptomatic or mild.

5 Dec, 2021 | 23:50h | UTC

Epidemiological update: Omicron variant of concern (VOC) – data as of 3 December 2021 (12.00) – European Centre for Disease Prevention and Control

Commentary on Twitter:

EUROPEAN EQUIVALENT OF CDC AS OF THIS AM: "All cases [of Omicron] for which there is available information on severity were either asymptomatic or mild. No deaths have been reported among these cases so far.". But let's keep on watching. https://t.co/3jHm4Wezi8

— Monica Gandhi MD, MPH (@MonicaGandhi9) December 3, 2021

Stay Updated in Your Specialty